Upgrades Summary - RBC Capital upgraded Nike (NKE) to Outperform from Sector Perform with a price target of $90, increased from $76, citing a "steeper revenue recovery" than market estimates due to new product contributions and World Cup sales [2] - Needham upgraded Amicus (FOLD) to Buy from Hold with a price target of $14, indicating reduced regulatory risk for Amicus' DMX-200 following FDA's decision regarding Travere's Filspari [2] - Goldman Sachs upgraded Stepstone Group (STEP) to Buy from Neutral with a price target of $83, up from $64, expecting a 25% CAGR in management fees from 2024-28 driven by growth in Private Wealth and record levels of shadow AUM [2] - RBC Capital upgraded CSX (CSX) to Outperform from Sector Perform with a price target of $39, increased from $37, viewing CSX shares as well positioned for consolidation scenarios in the railroad sector [2] - Scotiabank upgraded Vale (VALE) to Outperform from Sector Perform with a price target of $14, up from $12.50, anticipating benefits from the upcoming "decarbonization wave" [2]

Oracle TodayORCLOracle$293.90 -7.51 (-2.49%) 52-Week Range$118.86▼$345.72Dividend Yield0.68%P/E Ratio68.28Price Target$303.44Add to WatchlistOracle NYSE: ORCL will soon reach a trillion-dollar valuation, driven by the impact of AI on business operations. Once a bulky, cumbersome shackle, data has become a treasure trove for businesses, and Oracle is leading the charge to unlock it. Its fiscal Q1 results prove its leadership position with data and cloud-based data services, and the guidance suggests the str ...

We believe in the power of value investing, looking beyond short-term, conventional thinking to pursue long-term value. Since 1986, our global experience has generated investment insights and a range of differentiated fixed income, equity, and alternative solutions. As a specialist investment manager of Franklin Resources, Inc., Brandywine Global offers the advantages of an investment boutique backed by the resources and infrastructure of one of the world's leading asset managers. With headquarters in Phila ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Nvidia, once again, has stolen the show — specifically the chip titan's announcement of a massive investment in a struggling rival. The S&P 500 and the Nasdaq Composite touched fresh records on Thursday, with the indexes coming to life after a tepid response to a widely expected rate cut from the Federal Reserve on Wednesday. The catalyst? A $ 5 billion deal between Nvidia and Intel, which sparked a big rally led by chip stocks in early morning trading. Nvidia shares ticked rose 3%, while Intel soared a ...

Since my last analysis on Novo Nordisk A/S ( NVO ) (NOVO-B.CO), the company has gained over 17% in total return in just over a month. I believe that the market is waking up toAs a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjust ...

Core Viewpoint - Pine Labs Ltd., a digital payments provider in India, is planning to raise up to $700 million from an initial public offering (IPO) in the second half of October, having reduced its target from $1 billion due to existing investors scaling back their offer-for-sale portion [1][2][6]. Group 1: IPO Details - The IPO will consist of a fresh issue of shares worth 26 billion rupees ($295 million) and a sale of 147.8 million shares by the founder and investors, including Peak XV Partners, Pine Investment Holdings, and Invesco Investment Funds [2][6]. - The company has initiated roadshows for the planned share sale and has filed a draft prospectus with India's market regulator, receiving approval this month [7][6]. - Ongoing deliberations may lead to changes in details such as timing and the IPO size [2][6]. Group 2: Company Performance and Operations - Pine Labs reported a loss of 1.9 billion rupees on a revenue of 13.4 billion rupees for the year ending March 2024 [6]. - The company provides payment solutions, including point-of-sale terminals, and operates in India as well as international markets such as Singapore, Malaysia, and the UAE [6]. Group 3: Market Context - The IPO is taking place amid a government-driven digitization push that is fueling growth in the financial technology sector and a surge in primary market listings [2].

Madison Investments, an investment advisor, released its “Madison Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter started as a continuation of the first quarter. As the liberation day tariffs were catastrophic, sending both equities and treasuries steeply lower. Later, the administration set a pause in the tariff implementation, which led equities to rebound, supported by better-than-expected macroeconomic data, particularly regarding infl ...

Acquisition and Market Impact - Roche has agreed to acquire 89bio, a small biotech company, in a deal valued at up to $3.5 billion, which has led to a nearly doubling of 89bio's shares [1][2] - The acquisition highlights Roche's strategic move into the metabolic disorders sector, following previous collaborations and acquisitions aimed at obesity treatments [2] Product Potential - 89bio is developing a drug called pegozafermin, which targets metabolic dysfunction-associated steatohepatitis (MASH), a significant comorbidity linked to obesity, type 2 diabetes, and high blood pressure [1][3] - Roche's CEO expressed optimism about pegozafermin's potential to be a transformative treatment for MASH, addressing diverse patient needs associated with this complex disease [3] Market Reactions - Following the acquisition announcement, shares of 89bio surged approximately 86% in premarket trading, reaching a price of 15, while Roche's stock remained stable [3]

Market Performance - The S&P 500 index increased by 0.5% and is on track to surpass its previous record close from September 15 [1] - The Nasdaq Composite rose by 0.8%, also aiming for a record close [1] - The Dow Jones Industrial Average gained 54 points, reflecting a 0.1% increase [1] Federal Reserve Actions - The Federal Reserve recently lowered interest rates by a quarter of a point [2] - The Fed has forecasted two additional rate cuts by December and a third cut anticipated in 2026 [2]